Publications
P311
Mycoses. 2026, 69(4), e70170.
T. indotineae: A New Emergent Fungal Pathogen Driven by Global Travel.
P306
JAC-Antimicrobial Resistance, 2026, 8, 1.
Global epidemiology of azole resistance in Aspergillus fumigatus.
P305
Medical Mycology, 2025, 63, 12.
Multi-fungicide resistance in both clinical and environmental isolates of the human fungal pathogen Aspergillus fumigatus.
P303
npj Antimicrob. Resist., 2025, 3, 99.
Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.
P301
J. Med. Mycol. 2025, 101583.
A One Health Perspective on Diutina catenulata: Phenotypic Traits, Stress Sensitivity, and Virulence Across Diverse Isolates.
P297
Sci. Total Environ. 2025, 973, 179139.
Antifungal resistance in yeasts from One Health perspective: A Brazilian study.
P296
Curr. Res. Microb. Sci. 2025, 8, 100359.
Kodamaea ohmeri: An emergent yeast from a One Health perspective.
P295
Mycoses. 2025, 68, e70051
Antifungal Resistance in Non-fumigatus Aspergillus Species.
P294
Mycopathologia. 2025, 190, 59.
Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.
P293
mBio. 2025, e01320-25.
Small pangenome of Candida parapsilosis reflects overall low intraspecific diversity.
P292
Sci. Total Environ. 2025, 1000, 180385.
Agrochemical fungicides as environmental drivers of antifungal resistance.
P284
Nat. Commun. 2024, 15, 9190.
Alternative sulphur metabolism in the fungal pathogen Candida parapsilosis.
P283
Trends Microbiol. 2024, 32, 1042-1044.
Heteroresistance: a hidden cause behind antifungal prophylaxis failure.
P278
Antimicrob. Agents Chemother. 2024, e0002224.
Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis.
P276
Med. Mycol. 2023, 61, myad095.
Atovaquone exposure and Pneumocystis jirovecii cytochrome b mutations: French data and review of the literature.
P266
Microbiol. Resour. Announc. 2023, 12, e0126022.
Draft Genome Sequence of the Fluconazole-Resistant Yarrowia lipolytica Clinical Isolate CBS 18115.
P255
mBio. 2022, e0092022.
French mycoses study group. Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF network (2012 to 2018).
P253
mBio. 2022, e0177722.
Systematic analysis of copy number variations in the pathogenic yeast Candida parapsilosis identifies a gene amplification in RTA3 that is associated with drug resistance.
P252
Clin. Microbiol. Infect. 2022.
Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples.
P246
Microorganisms. 2022, 10, 104.
Impact of TR34/L98H, TR46/Y121F/T289A and TR53 alterations in azole‐resistant Aspergillus fumigatus on sterol composition and modifications after In Vitro exposure to itraconazole and voriconazole.
Autres publications scientifiques
PS40
Emerg. Infect. Dis. 2025, 31, 896-905.
Features of Invasive Aspergillosis Caused by Aspergillus flavus, France, 2012-2018.
PS08
J. Infect. Dis. 2022, 225, 868-880.
PRONOCYSTIS Study Group. Epidemiology and clinical impact of respiratory cinfections at diagnosis of Pneumocystis jirovecii pneumonia.
PS07
Antimicrob. Agents Chemother. 2022, 66, e0156321.
Highly conserved gsc1 gene of Pneumocystis jirovecii in patients with or without prior exposure to ehinocandins.
PS06
Parasite. 2022, 29.
Selecting a multiplex PCR panel for accurate molecular diagnosis of intestinal protists: a comparative study of Allplex® (Seegene®), G-DiaParaTrio (Diagenode®), and RIDA®GENE (R-Biopharm®) assays and microscopic examination.
Thèse
T27.
Bases moléculaires de la résistance aux azolés chez C. albicans et A. fumigatus.
Nantes, date de soutenance : 5 juillet 2012.